GSK Pharma Q3 FY26 PAT up 29% on consolidated basis, aided by land sale gain

Pat Growth 25pctExceptional ItemResults View source PDF Explain this filing

GLAXO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.2%Reaction day

₹2484.90

prior close

₹2512.70

announcement price

In-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+1.6%-0.4% vs market

Pharmaceuticals peers, median of 159sector+1.8%-0.6% vs sector

On the reaction day the stock moved 0.4 pts less than Nifty Midcap 150 and 0.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.2+1.6-0.4+1.8-0.6

Next day

+5.2+2.0+3.2+2.4+2.8

+8.7+2.0+6.7+2.0+6.7

+7.4+1.5+5.9+1.2+6.2

+4.2-0.2+4.4+0.7+3.6

+4.3+0.2+4.0+0.0+4.3

+4.0+1.1+2.9+0.7+3.3

15d

+1.9-2.1+3.9-4.4+6.2

+1.8-5.4+7.2-5.3+7.0

-5.1-4.4-0.8-2.9-2.2

-2.0+2.7-4.7+5.0-7.0

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 159Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

GSK Pharma Q3 FY26 standalone revenue rose 8% YoY to Rs 1,022.6 crores, with PAT up 21% to Rs 277.2 crores. Consolidated Q3 PAT grew 29% to Rs 295.6 crores, boosted by Rs 18 crores exceptional credit from sale of a non-operational land site. Nine-month standalone PAT rose 12% to Rs 736.9 crores; revenue up 1.6%. Q3 EPS was Rs 16.36 standalone. New Labour Codes added Rs 11.8 crores to staff costs. Limited review by Deloitte Haskins and Sells LLP was clean.

Likely market impact

Strong quarterly profit growth and one-time land sale gain lift earnings; underlying revenue growth remains modest at 1.6% for nine months.